Immune checkpoint blockade in locally advanced rectal cancer with deficient DNA mismatch repair: retrospective multicenter experience
Open Access
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapyCancer, 2025
- Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II populationAnnals of Oncology, 2025
- 542P Long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trialAnnals of Oncology, 2024
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialAnnals of Oncology, 2024
- Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal CancerJAMA Oncology, 2023
- Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Annals of Oncology, 2022
- EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patientsFamilial Cancer, 2012
- Long-Term Quality of Life in Patients with Rectal Cancer: Association with Severe Postoperative Complications and Presence of a StomaDiseases of the Colon & Rectum, 2009
- Urinary dysfunction after rectal cancer treatment is mainly caused by surgeryBritish Journal of Surgery, 2008